Clinical Proteomics

News on proteomics applications for clinical use in genetics, genomics, and molecular diagnostics.

The company is confident about bringing the test to market despite potential future competition and views it as an easy fit for its existing sales channels.

The deal gives Biodesix an additional test in the lung cancer space, Indi's XL2, which helps to classify lung nodules identified by imaging scans as benign or malignant.

Researchers affiliated with the Pancreatic Cancer Action Network found that treatment based on patient molecular profiles improved progression-free survival.

The company entered a securities purchase agreement through which it has raised gross proceeds of $650,000 and paid down a portion of the company's debt.

Freenome will leverage proteomics firm Biognosys' technology to add protein quantification to the development of Freenome's first commercially available screening test.